Suzhou Zelgen Biopharmaceuticals Co., Ltd.
SHH: 688266.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zelin Sheng
- Employees
- 867
- Headquarters
- Kunshan, China
- IPO year
- 2020
- Market cap
- CN¥26.9B
- Website
- https://www.zelgen.com
Loading 688266…
Loading profile data…Frequently asked questions about 688266
What does Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) do?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and...
Where does 688266.SS trade?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) trades on the Shanghai Stock Exchange.
What sector is 688266.SS in?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Suzhou Zelgen Biopharmaceuticals Co., Ltd.?
Zelin Sheng is the chief executive officer of Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS).
Where is Suzhou Zelgen Biopharmaceuticals Co., Ltd. headquartered?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is headquartered in China.
Does 688266.SS pay a dividend?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 688266.SS go public?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) completed its initial public offering in 2020.